Renal Cancer Detection With Liquid Biopsy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: GaGnostic, GaGnostic, GaGnostic.
- Who it may be relevant to
- Registry conditions: Renal Cancer, Oncocytoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.
Interventions
- Diagnostic test GaGnostic
Plasma - Diagnostic test GaGnostic
Serum - Diagnostic test GaGnostic
Urine
Primary outcome measures
- To identify the optimal GAG score [Time frame: 2 years]
- To identify the optimal GAG score [Time frame: 2 years]
- To identify the optimal GAG score [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer.
- For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)
- Sign up information consent
- Can perform protocol procedure
Exclusion criteria
- Non-clear cell Renal cell carcinoma
- RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
- Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Denmark · 1 center
- Zealand University Hospital — Roskilde
Identifiers
NCT: NCT05060783 · SJ-894